CoChat

Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis

Open access
Geven, Christopher, Kox, Matthijs, Pickkers, Peter · 2018 · Frontiers in Immunology
Cited by 135

The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.

Abstract

Sepsis remains a major medical challenge, for which, apart from improvements in supportive care, treatment has not relevantly changed over the last few decades. Vasodilation and vascular leakage play a pivotal role in the development of septic shock, with vascular leakage being caused by disrupted endothelial integrity. Adrenomedullin, a free circulating peptide involved in regulation of endothelial barrier function and vascular tone, is implicated in the pathophysiology of sepsis. Adrenomedullin levels are increased during sepsis, and correlate with extent of vasodilation, as well as with disease severity and mortality. In vitro and preclinical in vivo data show that administration of adrenomedullin exerts anti-inflammatory, antimicrobial, and protective effects on endothelial barrier function during sepsis, but other work suggests that it may also decrease blood pressure, which could be detrimental for patients with septic shock. Work has been carried out to negate adrenomedullins putative negative effects, while preserving or even potentiating its beneficial actions. Preclinical studies have demonstrated that the use of antibodies that bind to the n-terminus of adrenomedullin results in an overall increase of circulating adrenomedullin levels and improves sepsis outcome. Similar beneficial effects were obtained using co-administration of adrenomedullin and adrenomedullin binding protein-1. It is hypothesized that the mechanism behind the beneficial effects of adrenomedullin binding involves prolongation of its half-life and a shift of adrenomedullin from the interstitium to the circulation. This in turn results in increased adrenomedullin activity in the blood compartment, where it exerts beneficial endothelial-barrier stabilizing effects, whereas its detrimental vasodilatory effects in the interstitium are reduced. Up till now, in vivo data on adrenomedullin-targeted treatments in humans are lacking, however, the first study in septic patients with a n-terminus antibody (Adrecizumab) is currently being conducted.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.3389/fimmu.2018.00292

Cites

8 of 8 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 8 references

Cited by

See all 135

Metadata

Authors
Geven, C., Kox, M., & Pickkers, P.
Venue
Frontiers in Immunology
Published
2018-02-19
Volume
9
Pages
292-292
ISSN
1664-3224 (ISSN-L)
OpenAlex
W2791367003
Cited by
135
References
8
FWCI
9.20
Type
journal article
Language
en
Open access
gold

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis. https://app.cochat.ai/papers/10.3389/fimmu.2018.00292
The paper
Geven, C., Kox, M., & Pickkers, P. (2018). Adrenomedullin and Adrenomedullin-Targeted Therapy As Treatment Strategies Relevant for Sepsis. Frontiers in Immunology. https://doi.org/10.3389/fimmu.2018.00292

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.